Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KRT005
MIFTS: 47

Keratoacanthoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Keratoacanthoma

About this section

MalaCards integrated aliases for Keratoacanthoma:

Name: Keratoacanthoma 12 76 55 44 15 73

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3149
MeSH 44 D007636
NCIt 50 C3146
SNOMED-CT 68 58220003
UMLS 73 C0022572
Sources

Summaries for Keratoacanthoma

About this section
MalaCards based summary : Keratoacanthoma is related to verrucous carcinoma and keratosis, and has symptoms including pruritus and exanthema. An important gene associated with Keratoacanthoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Lidocaine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone, and related phenotypes are digestive/alimentary and integument

Wikipedia : 76 Keratoacanthoma (KA) is a common low-grade (unlikely to metastasize or invade) rapidly-growing skin... more...

Sources

Related Diseases for Keratoacanthoma

About this section

Diseases in the Keratoacanthoma family:

Familial Keratoacanthoma

Diseases related to Keratoacanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 verrucous carcinoma 30.1 KRT10 TP53
2 keratosis 30.1 DSG1 FLG KRT10
3 acanthoma 29.9 KRT10 KRT17
4 bowen's disease 29.9 KRT10 KRT16 KRT17 MKI67
5 actinic keratosis 29.9 FLG KRT17 TP53
6 basal cell carcinoma 29.8 CDKN1A KRT10 KRT16 KRT17 MKI67 TP53
7 lichen planus 29.7 FLG GZMB KRT10 KRT16 TP53
8 discoid lupus erythematosus 29.7 FLG GZMB KRT10 KRT16
9 papilloma 29.7 CDKN1A FLG KRT10 TP53
10 steatocystoma multiplex 29.6 KRT10 KRT16 KRT17
11 psoriasis 29.4 FLG KRT10 KRT16 KRT17
12 generalized eruptive keratoacanthoma 12.3
13 familial keratoacanthoma 12.2
14 vulvar keratoacanthoma-like carcinoma 12.0
15 multiple self-healing squamous epithelioma 11.9
16 muir-torre syndrome 11.7
17 palmoplantar carcinoma, multiple self-healing 11.3
18 squamous cell carcinoma 10.8
19 basal cell carcinoma 1 10.3
20 melanoma 10.3
21 cheilitis 10.3 MSH2 TP53
22 brain ependymoma 10.3 MKI67 TP53
23 spitz nevus 10.2 MKI67 TP53
24 oral leukoplakia 10.2 MKI67 TP53
25 lichen sclerosus 10.2 GZMB TP53
26 vulva squamous cell carcinoma 10.2 KRT17 TP53
27 adenosarcoma 10.2 MKI67 TP53
28 soft tissue sarcoma 10.2 MKI67 TP53
29 cervix uteri carcinoma in situ 10.2 KRT17 TP53
30 breast squamous cell carcinoma 10.2 KRT10 TP53
31 uterus carcinoma in situ 10.2 KRT17 TP53
32 embryonal sarcoma 10.2 MKI67 TP53
33 basal cell carcinoma, infundibulocystic 10.2 KRT10 KRT17
34 lupus erythematosus 10.2
35 large cell acanthoma 10.2 KRT10 KRT17
36 eccrine acrospiroma 10.2 KRT10 KRT17
37 cerebral primitive neuroectodermal tumor 10.2 MSH2 TP53
38 basaloid squamous cell carcinoma 10.2 KRT17 TP53
39 hidradenocarcinoma 10.2 MKI67 TP53
40 invasive bladder transitional cell carcinoma 10.2 CDKN1A TP53
41 appendix carcinoid tumor 10.2 MLH1 MSH2
42 bladder transitional cell papilloma 10.2 CDKN1A TP53
43 colorectal cancer, hereditary nonpolyposis, type 7 10.2 MLH1 MSH2
44 atypical follicular adenoma 10.2 CDKN1A TP53
45 adenosquamous colon carcinoma 10.2 MLH1 MSH2
46 necrotizing sialometaplasia 10.2 GZMB MKI67 TP53
47 sebaceous adenoma 10.2 MLH1 MSH2
48 lower lip cancer 10.2 MLH1 MSH2
49 anal fistula 10.1 MLH1 MSH2
50 striate palmoplantar keratoderma 10.1 DSG1 KRT10

Graphical network of the top 20 diseases related to Keratoacanthoma:



Diseases related to Keratoacanthoma
Sources

Symptoms & Phenotypes for Keratoacanthoma

About this section

UMLS symptoms related to Keratoacanthoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Keratoacanthoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 CDKN1A KRT16 KRT17 MLH1 MSH2 TP53
2 integument MP:0010771 9.17 CDKN1A DSG1 KRT16 KRT17 MLH1 MSH2
Sources

Drugs & Therapeutics for Keratoacanthoma

About this section

Drugs for Keratoacanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Azathioprine Approved Phase 4 446-86-6 2265
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
5
Everolimus Approved Phase 4 159351-69-6 6442177
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8 Immunologic Factors Phase 4,Phase 2
9 Cyclosporins Phase 4
10 Anesthetics, Local Phase 4
11 Anesthetics Phase 4
12 Peripheral Nervous System Agents Phase 4
13 Diuretics, Potassium Sparing Phase 4
14 Central Nervous System Depressants Phase 4
15 Sodium Channel Blockers Phase 4
16 Anti-Arrhythmia Agents Phase 4
17 Anti-Infective Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Antifungal Agents Phase 4
20 Calcineurin Inhibitors Phase 4
21 Immunosuppressive Agents Phase 4
22 Anti-Bacterial Agents Phase 4
23
Dabrafenib Approved, Investigational Phase 3,Phase 2 1195765-45-7 44462760 44516822
24
Trametinib Approved Phase 3,Phase 2 871700-17-3 11707110
25 Protein Kinase Inhibitors Phase 3,Phase 2
26
Nivolumab Approved Phase 2 946414-94-4
27 Antibodies, Monoclonal Phase 2
28 Antibodies Phase 2
29 Immunoglobulins Phase 2
30
Nicotinamide Approved, Investigational 98-92-0 936
31
Sorafenib Approved, Investigational 284461-73-0 216239 406563
32
Methotrexate Approved 59-05-2, 1959-05-2 126941
33
Niacin Approved, Investigational, Nutraceutical 59-67-6 938
34
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
35 Vitamin B3
36 Nicotinic Acids
37 Vitamins
38 Vitamin B9
39 Trace Elements
40 Micronutrients
41 Vitamin B Complex
42 Folate

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Pain Outcomes Following Intralesional Corticosteroid Injections Not yet recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
2 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
3 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Active, not recruiting NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
4 Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib Completed NCT02314143 Phase 2 Dabrafenib;Trametinib
5 Study of TVEC in Patients With Cutaneous Squamous Cell Cancer Recruiting NCT03714828 Phase 2 Injection of TVEC into target lesions - week 1-2;Injection of TVEC into target lesions 3wks after 1st injection;Injection of TVEC into target lesions 2wks after 2nd injection;Injection of TVEC into target lesions 2wks after 3rd injection
6 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
7 A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn NCT02068079 Phase 1 Vemurafenib and Trientine
8 Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old Recruiting NCT03155217
9 Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Recruiting NCT02185560 Sorafenib (Nexavar, BAY43-9006)
10 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis Recruiting NCT01617018

Search NIH Clinical Center for Keratoacanthoma

Cochrane evidence based reviews: keratoacanthoma

Sources

Genetic Tests for Keratoacanthoma

About this section
Sources

Anatomical Context for Keratoacanthoma

About this section

MalaCards organs/tissues related to Keratoacanthoma:

41
Skin, Lung, Bone, Tongue, Brain, Myeloid, Colon
Sources

Publications for Keratoacanthoma

About this section

Articles related to Keratoacanthoma:

(show top 50) (show all 733)
# Title Authors Year
1
Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report. ( 29368221 )
2018
2
A Multiple Recurrent Keratoacanthoma of the Lower Leg After Repeated Wide-Excision and Mohs Micrographic Surgery. ( 29953419 )
2018
3
Solitary Palmar Keratoacanthoma: Case Report. ( 29770284 )
2018
4
Topical aminolevulinic acid-photodynamic therapy in the treatment of keratoacanthoma: a case report. ( 29913213 )
2018
5
Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma. ( 29610614 )
2018
6
Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review. ( 29058335 )
2018
7
Keratoacanthoma ( 29763106 )
2018
8
Cutaneous intravascular CD30+ T-cell pseudolymphoma occurring in a regressing keratoacanthoma. ( 29369392 )
2018
9
Multiple keratoacanthoma and oral lichen planus successfully treated with systemic retinoids and review of multiple keratoacanthoma associated with lichen planus. ( 29577263 )
2018
10
KERATOACANTHOMA OF THE UPPER LIP: REVIEW OF THE LITERATURE AND REPORT OF CASE WITH CENTRAL UPPER LIP RECONSTRUCTION. ( 29578429 )
2018
11
Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. ( 30353913 )
2018
12
A prospective diagnostic study on povidone-iodine retention in lesions suspected to be squamous cell carcinoma or keratoacanthoma. ( 30109892 )
2018
13
Embedded Tooth: Unique Mimicker of Keratoacanthoma. ( 30144411 )
2018
14
Keratoacanthoma-like cutaneous metastases in a case of squamous cell carcinoma of the tongue. ( 30381581 )
2018
15
Case of keratoacanthoma centrifugum marginatum treated with acitretin. ( 30389737 )
2018
16
Multiple disseminated keratoacanthoma-like nodules: a rare form of distant metastases to the skin. ( 30429717 )
2018
17
Keratoacanthoma Centrifugum Marginatum with Spontaneous Regression and Its Possible Differential Diagnosis. ( 30483096 )
2018
18
Efficacy and Safety of Intralesional Methotrexate in the Treatment of a Large Keratoacanthoma of the Dorsal Hand in a 99-Year-Old Woman. ( 30519171 )
2018
19
Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use. ( 28584672 )
2017
20
Keratoacanthoma of the lip: A case report with emphasis on histogenesis. ( 28479697 )
2017
21
Fine and Benign, Until It Becomes Malignant: The Enigmatic Keratoacanthoma. ( 28705282 )
2017
22
Use of topical ephedrine and naphazoline in the treatment of a keratoacanthoma: two case reports. ( 28712267 )
2017
23
Advances in histopathological diagnosis of keratoacanthoma. ( 28256761 )
2017
24
Eruptive Keratoacanthoma-Like Discoid Lupus Erythematosus. ( 28816744 )
2017
25
Use of photodynamic therapy and acitretin in generalized eruptive keratoacanthoma of Grzybowski. ( 28948204 )
2017
26
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. ( 28501937 )
2017
27
Keratoacanthoma Centrifugum Marginatum: Response to Acitretin. ( 28270315 )
2017
28
Keratoacanthoma management: results of a survey of UK dermatologists and surgeons. ( 28758190 )
2017
29
Calcified Keratoacanthoma with Tumoral Calcinosis in a 10-year-old Boy: A mere Co-incidence? ( 29263542 )
2017
30
A Case of Exophytic Pilomatricoma Clinically Resembling Keratoacanthoma. ( 28392667 )
2017
31
Multiple keratoacanthoma centrifugum marginatum in a young boy, and review of the literature. ( 28543888 )
2017
32
Multiple keratoacanthoma centrifugum marginatum associated with juvenile idiopathic arthritis and persistent corneal epithelial defect: an unusual case. ( 28906090 )
2017
33
Complete regression of keratoacanthoma with topical tazarotene gel 0.1%: therapeutic and pathophysiological perspectives. ( 28895378 )
2017
34
Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient. ( 27805257 )
2017
35
Keratoacanthoma-like dermatofibroma: A dermoscopic challenge. ( 28087033 )
2017
36
Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma. ( 28454431 )
2017
37
Complete regression of crateriform verruca after partial biopsy: Another type of epithelial crateriform tumor or a subtype of keratoacanthoma? ( 29235666 )
2017
38
Keratoacanthoma-Like Growths of Incontinentia Pigmenti Successfully Treated with Intralesional Methotrexate. ( 28414858 )
2017
39
Keratoacanthoma formation after skin grafting: A brief report and pathophysiological hypothesis. ( 27273800 )
2017
40
Relationship between Human Papilloma Virus and Subungual Keratoacanthoma: Two Case Reports and the Outcomes of Surgical Treatment. ( 28232913 )
2017
41
Keratoacanthoma en plaque/nodule: A brief report of the clinicopathological features of five cases. ( 28332728 )
2017
42
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling. ( 28439948 )
2017
43
Keratoacanthoma centrifugum marginatum: an unusual clinical and histopathological diagnostic pitfall. ( 28730244 )
2017
44
Keratoacanthoma of the conjunctiva - case report and review of the literature. ( 29556663 )
2017
45
Subungual Keratoacanthoma in a Patient With Yellow Nail Syndrome. ( 27158885 )
2016
46
Keratoacanthoma of the conjunctiva in a young patient. ( 27463634 )
2016
47
Distal Digital Keratoacanthoma in Patients With Incontinentia Pigmenti. ( 26614487 )
2016
48
Human polyomavirus DNA detection in keratoacanthoma and Spitz naevus: no evidence for a causal role. ( 27993945 )
2016
49
Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma. ( 26782292 )
2016
50
The distinction of keratoacanthoma from various types of squamous cell carcinoma with crateriform architecture. ( 27670127 )
2016
Sources

Variations for Keratoacanthoma

About this section
Sources

Expression for Keratoacanthoma

About this section
Search GEO for disease gene expression data for Keratoacanthoma.
Sources

Pathways for Keratoacanthoma

About this section

Pathways related to Keratoacanthoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.61 CDKN1A MLH1 MSH2 TP53
2
Pathways in cancer 37
12.55 CDKN1A MLH1 MSH2 TP53
3
DNA Damage 4
12.02 CDKN1A MKI67 MLH1 MSH2 TP53
4
Transcriptional misregulation in cancer 37
11.99 CDKN1A GZMB TP53
5
Colorectal Cancer Metastasis 64
11.84 CDKN1A MLH1 MSH2 TP53
6
Keratinization 66
Show member pathways
 11.81 DSG1 FLG KRT10 KRT16 KRT17
7
Direct p53 effectors 1
11.68 CDKN1A MLH1 MSH2 TP53
8
Retinoblastoma (RB) in Cancer 1
11.6 CDKN1A RBP1 TP53
9
Glucocorticoid receptor regulatory network 1
11.55 CDKN1A KRT17 TP53
10
DNA damage_Role of Brca1 and Brca2 in DNA repair 22
11.31 MLH1 MSH2 TP53
11
Integrated Cancer Pathway 1
11.24 CDKN1A MSH2 TP53
12
Doxorubicin Pathway, Pharmacokinetics 61
Show member pathways
 11.15 MLH1 MSH2 TP53
13
GADD45 Pathway 64
11.08 CDKN1A TP53
14
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 61
11.02 MLH1 MSH2
15
TP53 Network 1
Show member pathways
 10.85 CDKN1A TP53
16
Platinum drug resistance 37
10.79 CDKN1A MLH1 MSH2 TP53
17
LncRNA-mediated mechanisms of therapeutic resistance 1
10.57 CDKN1A TP53
18
Transcriptional activation of p53 responsive genes 66
Show member pathways
 10.34 CDKN1A TP53
Sources

GO Terms for Keratoacanthoma

About this section

Cellular components related to Keratoacanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.91 CDKN1A DSG1 FLG GZMB KRT10 KRT16
2 condensed chromosome GO:0000793 9.32 MKI67 MLH1
3 mismatch repair complex GO:0032300 9.16 MLH1 MSH2
4 cornified envelope GO:0001533 9.13 DSG1 FLG KRT10
5 intermediate filament GO:0005882 8.92 FLG KRT10 KRT16 KRT17

Biological processes related to Keratoacanthoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.86 CDKN1A MLH1 MSH2 TP53
2 cell cycle arrest GO:0007050 9.7 CDKN1A MSH2 TP53
3 cellular response to ionizing radiation GO:0071479 9.61 CDKN1A TP53
4 intrinsic apoptotic signaling pathway GO:0097193 9.6 CDKN1A TP53
5 mismatch repair GO:0006298 9.59 MLH1 MSH2
6 positive regulation of reactive oxygen species metabolic process GO:2000379 9.58 CDKN1A TP53
7 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.58 MSH2 TP53
8 keratinocyte differentiation GO:0030216 9.58 FLG KRT10 KRT16
9 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.57 GZMB TP53
10 keratinization GO:0031424 9.56 DSG1 KRT10 KRT16 KRT17
11 response to X-ray GO:0010165 9.55 CDKN1A MSH2
12 establishment of skin barrier GO:0061436 9.54 FLG KRT16
13 somatic hypermutation of immunoglobulin genes GO:0016446 9.51 MLH1 MSH2
14 isotype switching GO:0045190 9.49 MLH1 MSH2
15 determination of adult lifespan GO:0008340 9.48 MSH2 TP53
16 replicative senescence GO:0090399 9.46 CDKN1A TP53
17 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 MLH1 MSH2
18 positive regulation of isotype switching to IgA isotypes GO:0048298 9.37 MLH1 MSH2
19 signal transduction by p53 class mediator GO:0072331 9.32 CDKN1A TP53
20 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MLH1 MSH2
21 cornification GO:0070268 9.02 DSG1 FLG KRT10 KRT16 KRT17
22 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.96 MLH1 MSH2

Molecular functions related to Keratoacanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of epidermis GO:0030280 9.26 FLG KRT10
2 mismatched DNA binding GO:0030983 9.16 MLH1 MSH2
3 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH2
4 structural molecule activity GO:0005198 8.92 FLG KRT10 KRT16 KRT17
Sources

Sources for Keratoacanthoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....